Mylan, Abbott Bury Hatchet Over Depakote ER

Law360, New York (June 5, 2008, 12:00 AM EDT) -- Mylan Pharmaceuticals Inc. and Abbott Laboratories have reached a truce in their long-standing battle over Depakote, as Mylan won permission to sell a knockoff version of Abbott's best-selling extended-release epilepsy drug.

West-Virginia based Mylan, a subsidiary of multinational Mylan Inc., disclosed Thursday in a filing with the U.S. Securities & Exchange Commission that it will enjoy a 180-day exclusivity period to sell a 500 mg version of divalproex ER tablets upon launching, scheduled to take place no later than Jan. 1, 2009.

Under the deal, which...
To view the full article, register now.